- Home
- IOVA vs BUSE Comparison
IOVA vs BUSE Comparison
Compare IOVA & BUSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- BUSE
- Stock Information
- Founded
- IOVA 2007
- BUSE 1868
- Country
- IOVA United States
- BUSE United States
- Employees
- IOVA N/A
- BUSE N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- BUSE Major Banks
- Sector
- IOVA Health Care
- BUSE Finance
- Exchange
- IOVA Nasdaq
- BUSE Nasdaq
- Market Cap
- IOVA 1.0B
- BUSE 1.9B
- IPO Year
- IOVA N/A
- BUSE N/A
- Fundamental
- Price
- IOVA $3.17
- BUSE $22.11
- Analyst Decision
- IOVA Strong Buy
- BUSE Buy
- Analyst Count
- IOVA 9
- BUSE 5
- Target Price
- IOVA $18.22
- BUSE $27.80
- AVG Volume (30 Days)
- IOVA 9.3M
- BUSE 555.0K
- Earning Date
- IOVA 05-08-2025
- BUSE 04-22-2025
- Dividend Yield
- IOVA N/A
- BUSE 4.52%
- EPS Growth
- IOVA N/A
- BUSE N/A
- EPS
- IOVA N/A
- BUSE 0.95
- Revenue
- IOVA $164,070,000.00
- BUSE $430,476,000.00
- Revenue This Year
- IOVA $182.20
- BUSE $65.20
- Revenue Next Year
- IOVA $62.10
- BUSE $12.01
- P/E Ratio
- IOVA N/A
- BUSE $23.16
- Revenue Growth
- IOVA 13698.99
- BUSE 0.48
- 52 Week Low
- IOVA $2.70
- BUSE $18.40
- 52 Week High
- IOVA $13.60
- BUSE $28.97
- Technical
- Relative Strength Index (RSI)
- IOVA 43.38
- BUSE 62.02
- Support Level
- IOVA $3.02
- BUSE $20.91
- Resistance Level
- IOVA $3.73
- BUSE $21.97
- Average True Range (ATR)
- IOVA 0.25
- BUSE 0.59
- MACD
- IOVA 0.01
- BUSE 0.23
- Stochastic Oscillator
- IOVA 25.33
- BUSE 94.81
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech and Wealth Management. The banking segment generates a vast majority of its revenue.